在正规刺激后,德克斯基托增强了通过ATPase活性来激活NLRP3的活性
Daniel Boy-Ruiz1, Juan Miguel Suarez-Rivero1, Inés Muela-Zarzuela1
1Department of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013, Seville, Spain.
Inflammopharmacology
|September 23, 2025
概括
德克斯基托 (DXK) 是一种常见的NSAID,意外地放大了人类巨细胞中的NLRP3炎症酶激活. 这一发现表明,在长时间使用DXK时,特别是在炎症条件下,应谨慎使用.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症细胞是关键的先天性免疫传感器,激活caspase-1和炎症.
- NLRP3炎症酶与许多炎症和免疫疾病有关.
- 德克斯基托 (DXK) 是一种非类固醇抗炎药物 (NSAID),没有先前对NLRP3炎症组影响进行评估.
研究的目的:
- 为了研究德克斯基托 (DXK) 对人类巨细胞NLRP3炎症酶激活的影响.
- 阐明DXK影响炎症酶介导的炎症反应的机制.
主要方法:
- 人类巨细胞用DXK和各种炎症体刺激物 (LPS,ATP,尼日里辛) 进行治疗.
- 测量IL-1β释放和细胞死亡以评估炎症酶激活.
- 进行了分子对接和ATPase测试,以确定DXK与NLRP3.3的相互作用.
- 评估了NLRP3抑制剂MCC950的作用.
主要成果:
- DXK显著增强了IL-1β的释放,并促进了细胞死亡,这表明NLRP3炎症酶激活增加.
- 发现DXK与NLRP3 NATCH域结合,促进ATP水解和随后的炎症酶激活.
- 与DXK和尼日里辛的联合治疗进一步增加了IL-1β的分泌.
- NLRP3抑制剂MCC950抵消了DXK的促炎作用.
结论:
- 德克斯基托通过激活巨细胞中的NLRP3炎症酶途径来放大炎症.
- DXK的机制涉及与NLRP3 NATCH域结合,并促进ATP的水解.
- 建议在长时间使用DXK时谨慎使用,特别是在由炎症体活动驱动的自身炎症性疾病患者中.
相关概念视频
NF-κB-dependent Signaling Pathway
9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.8K
The Unfolded Protein Response
6.3K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
6.3K
Regulation of the Unfolded Protein Response
2.9K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.9K
MAPK Signaling Cascades
7.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.9K
GPCRs Regulate Adenylyl Cylase Activity
7.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K
GPCR Desensitization
7.9K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.9K


